|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||82.25 - 86.34|
|52-week range||76.45 - 106.66|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||16.69|
|Forward dividend & yield||3.33 (3.75%)|
|Ex-dividend date||06 May 2022|
|1y target est||N/A|
Image source: The Motley Fool. Sanofi (NASDAQ: SNY)Q4 2022 Earnings CallFeb 03, 2023, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Eva Schaefer-Jansen May cause actual results to differ materially.
Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.
Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. Higher sales of Dupixent and other specialty medicines were offset by a decline in vaccine sales.